Heterogeneous Trial Endpoints Limit Evidence in Acute Kidney Injury

The Challenge of Standardizing Acute Kidney Injury Outcomes

Acute kidney injury remains a frequent and severe complication in the intensive care unit and following major surgical procedures, significantly increasing the risk of long-term morbidity and mortality [1, 2]. Despite its clinical impact, evaluating the efficacy of preventive measures such as amino acid supplementation or hemodynamic optimization is often complicated by inconsistent results across major trials [3, 4]. This inconsistency frequently stems from variations in how researchers define renal outcomes and the specific patient populations they enroll [5, 6]. Furthermore, the infrequent use of standardized classification systems, such as the Kidney Disease Improving Global Outcomes criteria, makes it difficult for clinicians to synthesize evidence from different studies [2, 7]. To identify barriers to evidence-based practice, a comprehensive new analysis examines the extent of this heterogeneity across a decade of clinical research, revealing how divergent trial designs complicate bedside decision-making.

Mapping a Decade of Clinical Evidence

To characterize the current state of renal research, the investigators conducted a scoping review following the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR), a standardized framework designed to ensure transparent and complete reporting of evidence synthesis. The investigation involved a comprehensive search of PubMed, Embase, Web of Science, and Cochrane CENTRAL, targeting randomized controlled trials published over a ten-year period between January 2014 and April 2024. The study population was broad, encompassing both adults and children who either presented with acute kidney injury or were identified as being at risk for the condition. This inclusive approach allowed the authors to capture the full spectrum of clinical trial designs currently used to inform bedside decision-making in nephrology and critical care.

The researchers initially screened 3921 abstracts, ultimately identifying 251 randomized controlled trials that met the inclusion criteria for the final analysis. To evaluate how these trials measured success or failure, the authors utilized the Core Outcome Measures in Effectiveness Trials (COMET) taxonomy, a standardized classification system used to categorize which clinical endpoints are measured and how they are defined. Each outcome was meticulously sorted according to its core area, core domain, specific domain, measurement method, and timing. By applying this rigorous taxonomy, the study aimed to pinpoint exactly where definitions diverge, such as the varying thresholds of serum creatinine or urine output used to trigger a diagnosis of renal failure across different clinical protocols.

Prevention Trials Rely Heavily on Short-Term Creatinine

The majority of the literature analyzed in this review focused on preventing the onset of kidney injury rather than treating established disease. Specifically, prevention trials represented 197 out of 251 included studies (78.5%). Within this subset, the researchers found a heavy concentration on immediate biological markers. Nearly all outcomes (194 of 197, or 98.5%) belonged to the Physiological/Clinical Core Area, a category encompassing measurable biological processes and clinical events. Furthermore, 186 of 197 (94%) outcomes were categorized in the Renal outcomes Core Domain, indicating that most researchers prioritized kidney-specific metrics over systemic or patient-centered outcomes such as quality of life or long-term survival.

When examining the specific domains within these prevention-focused studies, renal function was the most frequent domain, appearing in 162 of 197 studies (82%). In contrast, renal damage was a domain in only 15 of 197 prevention trials (7.5%). This distinction is critical for clinicians, as renal function typically refers to the filtration capacity of the kidney, whereas renal damage refers to structural injury to the parenchyma. The methods used to measure these outcomes were notably narrow. Measurements in prevention trials relied mainly on serum creatinine alone in 130 of 162 studies (80%), while measurements used serum creatinine combined with urine output in only 25 of 162 studies (15%). This reliance on creatinine alone may overlook early stages of injury where urine output decreases before a rise in creatinine is detectable, potentially delaying the recognition of clinical deterioration.

The timing of these assessments further limits the understanding of long-term patient trajectories. The study found that outcome assessment timing in prevention trials occurred between 48 and 72 hours in 65% of studies, while assessment at 7 days occurred in 22% of studies. For the practicing physician, this means that the vast majority of available evidence on acute kidney injury prevention is based on very short-term fluctuations in serum creatinine. Because most trials conclude their observation within the first week of an intervention, there remains a significant data gap regarding whether these early physiological changes translate into lasting preservation of kidney function or a reduced risk of progression to chronic kidney disease.

Divergent Metrics in Therapeutic Interventions

While the majority of research focuses on prevention, the study identified that therapeutic randomized controlled trials represented 54 out of 251 included studies (21.5%). These trials, which evaluate interventions for patients with established acute kidney injury, demonstrated a different distribution of outcome priorities compared to their prevention-focused counterparts. Specifically, 37 of 54 (69%) outcomes in therapeutic trials belonged to the Physiological/Clinical Core Area, focusing on biological markers and clinical events. Notably, there was a greater emphasis on hard clinical endpoints in this subset, as 14 of 54 (26%) outcomes belonged to the Mortality/Survival Core Area, reflecting the higher acuity and risk profile of patients already experiencing renal failure.

The specific renal outcomes reported in these therapeutic studies also varied significantly, reflecting the complexity of managing established injury. Renal outcomes in therapeutic trials (33 of 54, or 61%) included renal function (9 of 54, 17%), renal recovery (10 of 54, 19%), and the use of renal replacement therapy (3 of 54, 6%), which involves the use of dialysis or hemofiltration when kidneys fail. To quantify these outcomes, researchers utilized several distinct metrics. Measurements in therapeutic trials included serum creatinine (16 of 54, 30%), mortality (14 of 54, 26%), and estimated glomerular filtration rate (3 of 54, 6%). This diversity in measurement methods complicates the ability of clinicians to compare the efficacy of different treatments, as a study measuring recovery via creatinine may not be directly comparable to one using filtration rates.

The duration of patient monitoring in therapeutic trials also differed from prevention studies, providing a longer window into patient outcomes. The researchers found that outcome assessment timing in therapeutic trials occurred between 7 and 90 days. This extended follow-up is clinically relevant because it captures the transition from acute injury to either recovery or the development of chronic kidney disease. However, the lack of a standardized measurement window within this 7 to 90 day range remains a barrier to synthesizing evidence. For the practicing physician, these findings underscore that while therapeutic trials are more likely to track survival and recovery than prevention trials, the lack of uniform endpoints continues to limit the strength of evidence available for managing established acute kidney injury.

The Path Toward Standardized Clinical Endpoints

The systematic review of 251 randomized controlled trials demonstrates that outcome reporting is heterogeneous, a finding that directly impacts the ability of clinicians to synthesize data and apply it to patient care. This lack of uniformity in how acute kidney injury is defined, measured, and followed across studies creates a significant barrier to evidence-based practice. When trials utilize different biochemical markers or varying timeframes for assessment, such as the 48 to 72 hour window seen in 65% of prevention trials versus the 7 to 90 day window in therapeutic trials, the resulting data cannot be easily compared or combined to form a cohesive treatment strategy.

To address these inconsistencies, the researchers highlight the need for a standardized core outcome set, a consensus-based minimum collection of outcomes that should be measured and reported in all clinical trials for a specific health condition. Without such a framework, the medical community lacks a common language to evaluate the efficacy of interventions. This fragmentation prevents the performance of robust meta-analyses, which are essential for developing high-certainty clinical guidelines. For the practicing physician, this means that even a large volume of research may fail to provide a clear answer on which preventive or therapeutic measures are most effective for their patients.

Ultimately, the study authors argue that establishing a core outcome set is essential for the translation of trial data into bedside protocols. By standardizing the specific domains, measurement methods, and timing of assessments, future research can provide the clear, comparable evidence that clinicians require to make informed treatment decisions. Moving toward this standardized reporting model will ensure that the results of randomized controlled trials are not just statistically significant within a single study, but are clinically applicable across the broader landscape of renal care, leading to more predictable and improved patient outcomes.

References

1. Groote TV, Bormann E, Marcello M, et al. Implementation of a kidney protection strategy to prevent acute kidney injury after major surgery in high-risk patients identified by biomarkers: a systematic review and individual participant data meta-analysis of randomized controlled trials.. Intensive care medicine. 2026. doi:10.1007/s00134-026-08399-1

2. Passos RDH, Ramos JGR, Gobatto A, Caldas J, Macedo E, Batista PB. Inclusion and definition of acute renal dysfunction in critically ill patients in randomized controlled trials: a systematic review.. Critical care (London, England). 2018. doi:10.1186/s13054-018-2009-x

3. Jiang W, Shi K, Shao J, et al. Protective effect of intravenous amino acid on kidney function: A systematic review and meta-analysis of randomized controlled trials.. Journal of critical care. 2025. doi:10.1016/j.jcrc.2024.154937

4. Majeed MW, Finnegan E, Ruelas MG, et al. Effectiveness of amino acid supplementation in preventing acute kidney injury following cardiac surgery: A systematic review and meta-analysis of randomized controlled trials.. Acta anaesthesiologica Scandinavica. 2025. doi:10.1111/aas.70037

5. Wu X, Bai Z, Zhang Y, Ji D, He N, Xu Y. #1700 Heterogeneity in characteristics of target population and definitions of renal outcome on evaluating the renoprotective effect of GLP-1RA in patients with diabetes: a systematic review and meta-analysis of observational studies versus randomized controlled trials. Nephrology, Dialysis and Transplantation. 2025. doi:10.1093/ndt/gfaf116.0920

6. Konstantinidis I, Patel S, Camargo M, et al. Representation and reporting of kidney disease in cerebrovascular disease: A systematic review of randomized controlled trials.. PloS one. 2017. doi:10.1371/journal.pone.0176145

7. Hernandez A, Barboza JJ, Pasupuleti V, Piscoya A, Roman Y. Effects of sacubitril valsartan on renal function in adults with heart failure: a systematic review and meta analysis of randomised controlled trials. European Heart Journal. 2022. doi:10.1093/eurheartj/ehac544.958